SOLID TUMOURS:@0.084848:0.038601:0.266058:0.038601:0.266058:0.019343:0.084848:0.019343:0.011712:0.020438:0.010866:0.005315:0.017498:0.006515:0.010019:0.015405:0.021613:0.020438:0.015405:0.014276:0.011712
62:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
sum  of  the  grades  of  the  most  common :@0.084242:0.096166:0.480499:0.096166:0.480499:0.080410:0.084242:0.080410:0.007466:0.011699:0.018049:0.005330:0.003204:0.012604:0.006042:0.005330:0.003198:0.006523:0.011738:0.012508:0.005330:0.003194:0.012950:0.005792:0.013143:0.013181:0.012508:0.007466:0.005330:0.003204:0.012604:0.006042:0.005330:0.003198:0.006523:0.011738:0.012508:0.005330:0.003196:0.018049:0.012604:0.007466:0.006523:0.005330:0.003202:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.005330
and  the  second  most  common  growth :@0.084242:0.112755:0.480490:0.112755:0.480490:0.096999:0.084242:0.096999:0.013143:0.011738:0.013181:0.005330:0.005973:0.006523:0.011738:0.012508:0.005330:0.005967:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.005330:0.005967:0.018049:0.012604:0.007466:0.006523:0.005330:0.005969:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.005330:0.005961:0.012950:0.005711:0.012604:0.015990:0.006523:0.011738:0.005330
patterns  give  the  final  Gleason  Score  –:@0.084242:0.129344:0.475146:0.129344:0.475146:0.113588:0.084242:0.113588:0.013123:0.013143:0.006523:0.006523:0.012508:0.006188:0.011738:0.007466:0.005330:0.005390:0.012950:0.003848:0.010660:0.012508:0.005330:0.005390:0.006523:0.011738:0.012508:0.005330:0.005380:0.004686:0.004686:0.011738:0.013143:0.003848:0.005330:0.005386:0.016779:0.003848:0.012508:0.013143:0.007466:0.012604:0.011738:0.005330:0.005384:0.009583:0.012450:0.012604:0.005709:0.012508:0.005330:0.005386:0.009621
 :@0.475146:0.129344:0.480534:0.129344:0.480534:0.113311:0.475146:0.113311:0.005388
e.g., 3 + 4   7. The higher Gleason Scores :@0.084242:0.145934:0.480465:0.145934:0.480465:0.130178:0.084242:0.130178:0.012508:0.005330:0.012950:0.005330:0.005330:0.006646:0.010660:0.006658:0.011661:0.006658:0.010660:0.005330:0.012488:0.006658:0.010660:0.005330:0.006658:0.008197:0.011738:0.012508:0.006648:0.011738:0.003848:0.012950:0.011738:0.012508:0.005792:0.006648:0.016779:0.003848:0.012508:0.013143:0.007466:0.012604:0.011738:0.006658:0.009583:0.012450:0.012604:0.005709:0.012508:0.007466:0.005330
=:@0.185292:0.147786:0.196453:0.147786:0.196453:0.129940:0.185292:0.129940:0.011161
(e.g., 8-10) have the worst prognosis.:@0.084242:0.162523:0.424927:0.162523:0.424927:0.146767:0.084242:0.146767:0.007100:0.012508:0.005330:0.012950:0.005330:0.005330:0.005330:0.010660:0.006388:0.010660:0.010660:0.007100:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330:0.006523:0.011738:0.012508:0.005330:0.015990:0.012604:0.005792:0.007466:0.006523:0.005330:0.013123:0.005694:0.012604:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.005330
PROSTATE RISK-BASED APPROACH :@0.084242:0.196371:0.469946:0.196371:0.469946:0.176774:0.084242:0.176774:0.013170:0.013641:0.019756:0.012230:0.009878:0.017404:0.009878:0.012230:0.006585:0.013641:0.006585:0.012230:0.014581:0.009878:0.013641:0.017404:0.012230:0.012230:0.016463:0.006585:0.017404:0.013170:0.013170:0.013641:0.019756:0.017404:0.018344:0.015993:0.006585
TO TREATMENT:@0.084242:0.215903:0.244168:0.215903:0.244168:0.196306:0.084242:0.196306:0.009878:0.019756:0.006585:0.009878:0.013641:0.012230:0.017404:0.009878:0.021167:0.012230:0.017404:0.009878
RISK FACTORS AND STRATIFICATION:@0.084242:0.235113:0.445572:0.235113:0.445572:0.217298:0.084242:0.217298:0.012401:0.005987:0.011118:0.013256:0.005987:0.010263:0.015822:0.016677:0.008980:0.017960:0.012401:0.011118:0.005987:0.015822:0.015822:0.014966:0.005987:0.011118:0.008980:0.012401:0.015822:0.008980:0.005987:0.010263:0.005987:0.016677:0.015822:0.008980:0.005987:0.017960:0.015822
The following factors play a role in selecting :@0.084242:0.252853:0.480482:0.252853:0.480482:0.237097:0.084242:0.237097:0.008005:0.011545:0.012315:0.004376:0.005850:0.012411:0.003656:0.003656:0.012411:0.015798:0.003656:0.011545:0.012758:0.004376:0.005850:0.012950:0.012257:0.006331:0.012411:0.005600:0.007274:0.004374:0.012931:0.003656:0.012950:0.010122:0.004374:0.012950:0.004376:0.005519:0.012411:0.003656:0.012315:0.004374:0.003656:0.011545:0.004374:0.007274:0.012315:0.003656:0.012315:0.012257:0.006331:0.003656:0.011545:0.012946:0.005330
the correct initial treatment: anatomic ex-:@0.084242:0.269442:0.475165:0.269442:0.475165:0.253686:0.084242:0.253686:0.006331:0.011545:0.012315:0.006850:0.012257:0.012411:0.005600:0.005519:0.012315:0.012257:0.006331:0.006850:0.003656:0.011545:0.003656:0.006331:0.003656:0.012950:0.003656:0.006850:0.006331:0.005521:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.005138:0.006850:0.012950:0.011545:0.012950:0.006331:0.012411:0.017857:0.003656:0.012257:0.006850:0.012315:0.009044:0.006388
tent of disease (The American Joint Com-:@0.084242:0.286032:0.475210:0.286032:0.475210:0.270276:0.084242:0.270276:0.006331:0.012315:0.011545:0.006331:0.007206:0.012411:0.005850:0.007216:0.012989:0.003656:0.007274:0.012315:0.012950:0.007274:0.012315:0.007206:0.006908:0.008005:0.011545:0.012315:0.007216:0.014047:0.017857:0.012315:0.005600:0.003656:0.012257:0.012950:0.011545:0.007216:0.009082:0.012411:0.003656:0.011545:0.006331:0.007216:0.015452:0.012411:0.017857:0.006388
mittee on Cancer [AJCC] TNM stage), his-:@0.084242:0.302621:0.475152:0.302621:0.475152:0.286865:0.084242:0.286865:0.017857:0.003656:0.006331:0.006331:0.012315:0.012315:0.006465:0.012411:0.011545:0.006465:0.015452:0.012950:0.011545:0.012257:0.012315:0.005600:0.006465:0.006562:0.014047:0.009082:0.015452:0.015452:0.006562:0.006465:0.008005:0.014047:0.017491:0.006465:0.007274:0.006331:0.012950:0.012758:0.012315:0.006908:0.005138:0.006465:0.011545:0.003656:0.007274:0.006388
tological  grade  (Gleason/Grade  group), :@0.084242:0.319210:0.480488:0.319210:0.480488:0.303454:0.084242:0.303454:0.006331:0.012411:0.003656:0.012411:0.012758:0.003656:0.012257:0.012950:0.003656:0.005330:0.006186:0.012758:0.005600:0.012950:0.012989:0.012315:0.005330:0.006186:0.006908:0.016587:0.003656:0.012315:0.012950:0.007274:0.012411:0.011545:0.008217:0.016587:0.005600:0.012950:0.012989:0.012315:0.005330:0.006186:0.012758:0.005521:0.012411:0.011507:0.012931:0.006908:0.005328:0.005330
PSA, expected outcome of each treat-:@0.084242:0.335800:0.475169:0.335800:0.475169:0.320044:0.084242:0.320044:0.011199:0.009390:0.014047:0.005138:0.011680:0.012315:0.009044:0.012931:0.012315:0.012257:0.006331:0.012315:0.012989:0.011680:0.012411:0.011507:0.006331:0.012257:0.012411:0.017857:0.012315:0.011680:0.012411:0.005850:0.011680:0.012315:0.012950:0.012257:0.011545:0.011680:0.006331:0.005521:0.012315:0.012950:0.006331:0.006388
ment, potential complications of each :@0.084242:0.352389:0.480480:0.352389:0.480480:0.336633:0.084242:0.336633:0.017857:0.012315:0.011545:0.006331:0.005138:0.014720:0.012931:0.012411:0.006331:0.012315:0.011545:0.006331:0.003656:0.012950:0.003656:0.014720:0.012257:0.012411:0.017857:0.012931:0.003656:0.003656:0.012257:0.012950:0.006331:0.003656:0.012411:0.011545:0.007274:0.014720:0.012411:0.005850:0.014720:0.012315:0.012950:0.012257:0.011736:0.005330
treatment and patient’s general condition: :@0.084242:0.368978:0.480495:0.368978:0.480495:0.353223:0.084242:0.353223:0.006331:0.005519:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.004695:0.012950:0.011545:0.012989:0.004695:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.006562:0.007274:0.004695:0.012758:0.012315:0.011545:0.012315:0.005600:0.012950:0.003656:0.004695:0.012257:0.012411:0.011545:0.012989:0.003656:0.006331:0.003656:0.012411:0.011545:0.005328:0.005330
life expectancy and comorbidities.:@0.084242:0.385568:0.403358:0.385568:0.403358:0.369812:0.084242:0.369812:0.003656:0.003656:0.005850:0.012315:0.005138:0.012315:0.009044:0.012931:0.012315:0.012257:0.006331:0.012950:0.011545:0.012257:0.010122:0.005138:0.012950:0.011545:0.012989:0.005138:0.012257:0.012411:0.017857:0.012411:0.005600:0.012931:0.003656:0.012989:0.003656:0.006331:0.003656:0.012315:0.007274:0.005330
Since 2014, the International Society of :@0.102426:0.402157:0.480499:0.402157:0.480499:0.386401:0.102426:0.386401:0.009583:0.003848:0.011738:0.012450:0.012508:0.007899:0.010660:0.010660:0.010660:0.010660:0.005330:0.007909:0.006523:0.011738:0.012508:0.007909:0.004349:0.011738:0.006523:0.012508:0.006186:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.007899:0.009583:0.012604:0.012450:0.003848:0.012508:0.006523:0.010314:0.007897:0.012604:0.006042:0.005330
Urological Pathology  (ISUP)  consensus :@0.084242:0.418747:0.480485:0.418784:0.480485:0.403028:0.084242:0.402991:0.012604:0.005709:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.016241:0.011392:0.013143:0.006523:0.011738:0.012604:0.003848:0.012604:0.012950:0.010314:0.005330:0.010899:0.007100:0.004349:0.009583:0.012604:0.011392:0.007100:0.006216:0.016241:0.012450:0.012604:0.011738:0.007466:0.012508:0.011738:0.007466:0.011699:0.007466:0.393168
5:@0.357562:0.413165:0.363777:0.413165:0.363777:0.403979:0.357562:0.403979:0.006215
group  has implemented  the  new  Grade :@0.084245:0.435373:0.480489:0.435373:0.480489:0.419617:0.084245:0.419617:0.012950:0.005709:0.012604:0.011699:0.013123:0.005330:0.003506:0.011738:0.013143:0.007466:0.008852:0.003848:0.018049:0.013123:0.003848:0.012508:0.018049:0.012508:0.011738:0.006523:0.012508:0.013181:0.005330:0.003502:0.006523:0.011738:0.012508:0.005330:0.003504:0.011738:0.012508:0.015990:0.005330:0.003506:0.016779:0.005792:0.013143:0.013181:0.012508:0.005330
Group system which uses the traditional :@0.084245:0.451963:0.480464:0.451963:0.480464:0.436207:0.084245:0.436207:0.016779:0.005713:0.012604:0.011699:0.013123:0.009756:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.009756:0.015990:0.011738:0.003848:0.012450:0.011738:0.009756:0.011699:0.007466:0.012508:0.007466:0.009756:0.006523:0.011738:0.012508:0.009756:0.006523:0.005792:0.013143:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330
Gleason scoring to classify findings in five :@0.084245:0.468552:0.480492:0.468552:0.480492:0.452796:0.084245:0.452796:0.016779:0.003848:0.012508:0.013143:0.007466:0.012604:0.011738:0.007310:0.007466:0.012450:0.012604:0.005792:0.003848:0.011738:0.012950:0.007301:0.006523:0.012604:0.007302:0.012450:0.003848:0.013143:0.007466:0.007466:0.003848:0.006042:0.010314:0.007326:0.004686:0.004686:0.011738:0.013181:0.003848:0.011738:0.012950:0.007466:0.007312:0.003848:0.011738:0.007310:0.004686:0.004686:0.010660:0.012508:0.005330
groups (see Table 1).:@0.084245:0.485141:0.276277:0.485141:0.276277:0.469385:0.084245:0.469385:0.012950:0.005709:0.012604:0.011699:0.013123:0.007466:0.005330:0.007100:0.007466:0.012508:0.012508:0.005330:0.007195:0.013143:0.013123:0.003848:0.012508:0.005330:0.010660:0.007100:0.005330
The  National Comprehensive Cancer :@0.102429:0.501731:0.480506:0.501731:0.480506:0.485975:0.102429:0.485975:0.008197:0.011738:0.012508:0.005330:0.008607:0.014239:0.013143:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.013951:0.015644:0.012604:0.018049:0.013123:0.005711:0.012508:0.011738:0.012508:0.011738:0.007466:0.003848:0.010660:0.012508:0.013951:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330
Network  (NCCN) guidelines recommend :@0.084245:0.518320:0.480500:0.518320:0.480500:0.502564:0.084245:0.502564:0.014239:0.012508:0.006523:0.015990:0.012604:0.005792:0.009660:0.005330:0.004405:0.007100:0.014239:0.015644:0.015644:0.014239:0.007100:0.009756:0.012950:0.011699:0.003848:0.013181:0.012508:0.003848:0.003848:0.011738:0.012508:0.007466:0.009756:0.005713:0.012508:0.012450:0.012604:0.018049:0.018049:0.012508:0.011738:0.013181:0.005330
that risk-appropriate treatment should be :@0.084245:0.534909:0.480485:0.534909:0.480485:0.519153:0.084245:0.519153:0.006523:0.011738:0.013143:0.006523:0.006947:0.005792:0.003848:0.007466:0.009660:0.006388:0.013143:0.013123:0.013123:0.005721:0.012604:0.013123:0.005792:0.003848:0.013143:0.006523:0.012508:0.006947:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006947:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.006947:0.013123:0.012508:0.005330
offered to patients. Very low-, low-, inter-:@0.084245:0.551499:0.475170:0.551499:0.475170:0.535743:0.084245:0.535743:0.012604:0.006094:0.006042:0.012508:0.005709:0.012508:0.013181:0.007947:0.006523:0.012604:0.007936:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.007936:0.011567:0.012508:0.005792:0.010314:0.007937:0.003848:0.012604:0.015990:0.006388:0.005330:0.007947:0.003848:0.012604:0.015990:0.006388:0.005330:0.007947:0.003848:0.011738:0.006523:0.012508:0.005792:0.006388
mediate-, high- and very high-risk groups :@0.084245:0.568088:0.480510:0.568088:0.480510:0.552332:0.084245:0.552332:0.018049:0.012508:0.013181:0.003848:0.013143:0.006523:0.012508:0.006388:0.005330:0.007697:0.011738:0.003848:0.012950:0.011738:0.006388:0.007687:0.013143:0.011738:0.013181:0.007697:0.010660:0.012508:0.005792:0.010314:0.007697:0.011738:0.003848:0.012950:0.011738:0.006388:0.005792:0.003848:0.007466:0.009660:0.007697:0.012950:0.005711:0.012604:0.011699:0.013123:0.007466:0.005330
are  identified.  For  each,  group-specific :@0.523645:0.096138:0.919879:0.096138:0.919879:0.080382:0.523645:0.080382:0.013143:0.005715:0.012508:0.005330:0.007403:0.003848:0.013181:0.012508:0.011738:0.006523:0.003848:0.004686:0.004686:0.012508:0.013181:0.005330:0.005330:0.007397:0.009333:0.012604:0.005792:0.005330:0.007395:0.012508:0.013143:0.012450:0.011738:0.005330:0.005330:0.007401:0.012950:0.005709:0.012604:0.011699:0.013123:0.006388:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.005330
options  are recommended. Metastatic :@0.523645:0.113693:0.919899:0.113693:0.919899:0.097937:0.523645:0.097937:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.009342:0.013143:0.005715:0.012508:0.014682:0.005713:0.012508:0.012450:0.012604:0.018049:0.018049:0.012508:0.011738:0.013181:0.012508:0.013181:0.005317:0.014682:0.017684:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330
disease is set out as a separate entity with :@0.523645:0.131248:0.919885:0.131248:0.919885:0.115492:0.523645:0.115492:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005580:0.003848:0.007466:0.005580:0.007466:0.012508:0.006523:0.005580:0.012604:0.011699:0.006523:0.005580:0.013143:0.007466:0.005580:0.013143:0.005580:0.007466:0.012508:0.013123:0.013143:0.005792:0.013143:0.006523:0.012508:0.005580:0.012508:0.011738:0.006523:0.003848:0.006523:0.010314:0.005580:0.015990:0.003848:0.006523:0.011738:0.005330
different treatment lines.:@0.523645:0.148803:0.750419:0.148803:0.750419:0.133047:0.523645:0.133047:0.013181:0.003848:0.006102:0.006042:0.012508:0.005711:0.012508:0.011738:0.006523:0.005330:0.006523:0.005700:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.003848:0.003848:0.011738:0.012508:0.007466:0.005330
Table 2 explains the various risks groups. :@0.541830:0.166358:0.919874:0.166358:0.919874:0.150602:0.541830:0.150602:0.007197:0.013143:0.013123:0.003848:0.012508:0.006369:0.010660:0.006369:0.012508:0.009236:0.013123:0.003848:0.013143:0.003848:0.011738:0.007466:0.006383:0.006523:0.011738:0.012508:0.006369:0.010660:0.013143:0.005792:0.003848:0.012604:0.011699:0.007466:0.006369:0.005792:0.003848:0.007466:0.009660:0.007466:0.006369:0.012950:0.005709:0.012604:0.011699:0.013123:0.007466:0.005330:0.005330
Very-low-risk patients must have disease :@0.523645:0.183913:0.919868:0.183913:0.919868:0.168157:0.523645:0.168157:0.011567:0.012508:0.005792:0.010314:0.006388:0.003848:0.012604:0.015990:0.006388:0.005792:0.003848:0.007466:0.009660:0.010487:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.010487:0.018049:0.011699:0.007466:0.006523:0.010487:0.011738:0.013143:0.010660:0.012508:0.010487:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330
that is detectable by PSA only (i.e., not on :@0.523645:0.201468:0.919895:0.201468:0.919895:0.185712:0.523645:0.185712:0.006523:0.011738:0.013143:0.006523:0.005446:0.003848:0.007466:0.005446:0.013181:0.012508:0.006523:0.012508:0.012450:0.006523:0.013143:0.013123:0.003848:0.012508:0.005446:0.013123:0.010314:0.005446:0.011392:0.009583:0.014239:0.005446:0.012604:0.011738:0.003848:0.010314:0.005446:0.007100:0.003848:0.005330:0.012508:0.005330:0.005330:0.005446:0.011738:0.012604:0.006523:0.005436:0.012604:0.011738:0.005330
imaging or DRE) with Grade Group 1 dis-:@0.523645:0.219023:0.914536:0.219023:0.914536:0.203267:0.523645:0.203267:0.003848:0.018049:0.013143:0.012950:0.003848:0.011738:0.012950:0.007370:0.012604:0.005792:0.007370:0.014316:0.011680:0.010314:0.007100:0.007370:0.015990:0.003848:0.006523:0.011738:0.007370:0.016779:0.005792:0.013143:0.013181:0.012508:0.007370:0.016779:0.005715:0.012604:0.011699:0.013123:0.007370:0.010660:0.007370:0.013181:0.003848:0.007466:0.006388
ease and PSA <10.:@0.523645:0.236578:0.696846:0.236578:0.696846:0.220823:0.523645:0.220823:0.012508:0.013143:0.007466:0.012508:0.005330:0.013143:0.011738:0.013181:0.005330:0.011392:0.009583:0.014239:0.005330:0.011661:0.010660:0.010660:0.005330
Table 1. International Society  :@0.524261:0.267998:0.797292:0.267998:0.797292:0.251964:0.524261:0.251964:0.007889:0.012508:0.012508:0.004426:0.012123:0.005195:0.010583:0.005195:0.005195:0.005195:0.011353:0.005580:0.012123:0.005965:0.011353:0.012508:0.005580:0.004426:0.012123:0.011353:0.012508:0.004426:0.005195:0.009814:0.012123:0.012123:0.004426:0.012123:0.005580:0.011163:0.004982:0.005388
of Urological Pathology (ISUP)  :@0.524261:0.284164:0.804604:0.284164:0.804604:0.268130:0.524261:0.268130:0.012123:0.005195:0.005195:0.012123:0.005965:0.012123:0.004426:0.012123:0.012508:0.004426:0.012123:0.012508:0.004426:0.005195:0.010583:0.012508:0.005580:0.011353:0.012123:0.004426:0.012123:0.012508:0.010968:0.005195:0.007120:0.005195:0.009814:0.012123:0.010583:0.007310:0.004986:0.005388
Grade Group classification system:@0.524261:0.300330:0.838095:0.300330:0.838095:0.284296:0.524261:0.284296:0.015971:0.005965:0.012508:0.012508:0.012123:0.005195:0.015971:0.005965:0.012123:0.011353:0.012508:0.005195:0.012123:0.004426:0.012508:0.008274:0.008274:0.004426:0.004907:0.004897:0.012123:0.012508:0.005580:0.004426:0.012123:0.011353:0.005195:0.008274:0.010968:0.008274:0.005580:0.012123:0.018088
Grade  Gleason score and pattern:@0.533867:0.331131:0.859391:0.331131:0.859391:0.315097:0.533867:0.315097:0.015971:0.005965:0.012508:0.012508:0.012317:0.005388:0.015719:0.015971:0.004426:0.012123:0.012508:0.008274:0.012123:0.011353:0.005195:0.008274:0.012123:0.012123:0.005965:0.012123:0.005195:0.012508:0.011353:0.012508:0.005195:0.012508:0.012508:0.005580:0.005580:0.012123:0.005965:0.011545
group:@0.533867:0.347297:0.588516:0.347297:0.588516:0.331263:0.533867:0.331263:0.012508:0.005965:0.012123:0.011353:0.012700
1:@0.533867:0.369720:0.544528:0.369720:0.544528:0.353964:0.533867:0.353964:0.010660
Grade 6 (3+3):@0.614243:0.369720:0.744148:0.369720:0.744148:0.353964:0.614243:0.353964:0.016779:0.005792:0.013143:0.013181:0.012508:0.005330:0.010660:0.005330:0.007100:0.010660:0.011661:0.010660:0.007100
2:@0.533867:0.392144:0.544528:0.392144:0.544528:0.376388:0.533867:0.376388:0.010660
Grade 7 (3+4):@0.614243:0.392144:0.744148:0.392144:0.744148:0.376388:0.614243:0.376388:0.016779:0.005792:0.013143:0.013181:0.012508:0.005330:0.010660:0.005330:0.007100:0.010660:0.011661:0.010660:0.007100
3:@0.533867:0.414567:0.544528:0.414567:0.544528:0.398811:0.533867:0.398811:0.010660
Grade 7 (4+3):@0.614243:0.414567:0.744148:0.414567:0.744148:0.398811:0.614243:0.398811:0.016779:0.005792:0.013143:0.013181:0.012508:0.005330:0.010660:0.005330:0.007100:0.010660:0.011661:0.010660:0.007100
4:@0.533867:0.436991:0.544528:0.436991:0.544528:0.421235:0.533867:0.421235:0.010660
Grade 8 (4+4, 3+5, or 5+3):@0.614243:0.436991:0.855158:0.436991:0.855158:0.421235:0.614243:0.421235:0.016779:0.005792:0.013143:0.013181:0.012508:0.005330:0.010660:0.005330:0.007100:0.010660:0.011661:0.010660:0.005330:0.005330:0.010660:0.011661:0.010660:0.005330:0.005330:0.012604:0.005792:0.005330:0.010660:0.011661:0.010660:0.007100
5:@0.533867:0.459414:0.544528:0.459414:0.544528:0.443658:0.533867:0.443658:0.010660
Grade 9 or 10 (4+5, 5+4, or 5+5):@0.614243:0.459414:0.905511:0.459414:0.905511:0.443658:0.614243:0.443658:0.016779:0.005792:0.013143:0.013181:0.012508:0.005330:0.010660:0.005330:0.012604:0.005792:0.005319:0.010660:0.010660:0.005330:0.007100:0.010660:0.011661:0.010660:0.005330:0.005330:0.010660:0.011661:0.010660:0.005330:0.005330:0.012604:0.005792:0.005319:0.010660:0.011661:0.010660:0.007100
Source: Adapted from Epstein JI, Egevad L, Amin :@0.524242:0.486943:0.882266:0.486943:0.882266:0.474688:0.524242:0.474688:0.007453:0.009803:0.009100:0.004505:0.009683:0.009728:0.004146:0.004146:0.011075:0.010252:0.010222:0.010207:0.005074:0.009728:0.010252:0.004146:0.004699:0.004505:0.009803:0.014038:0.004146:0.008022:0.010207:0.005807:0.005074:0.009728:0.002993:0.009129:0.004146:0.007214:0.003382:0.004146:0.004146:0.008022:0.010072:0.009728:0.008291:0.010222:0.010252:0.004146:0.006914:0.004146:0.004146:0.011075:0.014038:0.002993:0.009129:0.004146
MB, :@0.524242:0.500175:0.554878:0.500175:0.554878:0.487920:0.524242:0.487920:0.013754:0.008591:0.004146:0.004146
et al. :@0.554878:0.500175:0.595332:0.500175:0.595332:0.487920:0.554878:0.487920:0.009728:0.005074:0.004146:0.010222:0.002993:0.004146:0.004146
The 2014 International Society of Urological :@0.595332:0.500175:0.910119:0.500175:0.910119:0.487920:0.595332:0.487920:0.006376:0.009129:0.009728:0.004146:0.008291:0.008291:0.008291:0.008291:0.004146:0.003382:0.009129:0.005074:0.009728:0.004505:0.009129:0.010222:0.005074:0.002993:0.009803:0.009129:0.010222:0.002993:0.004146:0.007453:0.009803:0.009683:0.002993:0.009728:0.005074:0.008022:0.004146:0.009803:0.004699:0.004146:0.009803:0.004505:0.009803:0.002993:0.009803:0.010072:0.002993:0.009683:0.010222:0.002993:0.004146
Pathology (ISUP), Consensus Conference on Gleason :@0.524242:0.513407:0.912229:0.513407:0.912229:0.501152:0.524242:0.501152:0.008860:0.010222:0.005074:0.009129:0.009803:0.002993:0.009803:0.010072:0.008022:0.004146:0.005523:0.003382:0.007453:0.009803:0.008860:0.005523:0.004146:0.004146:0.012168:0.009803:0.009129:0.005807:0.009728:0.009129:0.005807:0.009100:0.005807:0.004146:0.012168:0.009803:0.009129:0.004699:0.009728:0.004505:0.009728:0.009129:0.009683:0.009728:0.004146:0.009803:0.009129:0.004146:0.013051:0.002993:0.009728:0.010222:0.005807:0.009803:0.009129:0.004146
Grading of Prostatic Carcinoma: Definition of Grading :@0.524242:0.526639:0.918919:0.526639:0.918919:0.514384:0.524242:0.514384:0.013051:0.004505:0.010222:0.010252:0.002993:0.009129:0.010072:0.004146:0.009803:0.004699:0.004146:0.008860:0.004505:0.009803:0.005807:0.005074:0.010222:0.005074:0.002993:0.009683:0.004146:0.012168:0.010222:0.004505:0.009683:0.002993:0.009129:0.009803:0.014038:0.010222:0.004146:0.004146:0.011135:0.009728:0.003644:0.003644:0.009129:0.002993:0.005074:0.002993:0.009803:0.009129:0.004146:0.009803:0.004699:0.004146:0.013051:0.004505:0.010222:0.010252:0.002993:0.009129:0.010072:0.004146
Patterns and Proposal for a New Grading System. :@0.524242:0.539871:0.884571:0.539871:0.884571:0.527616:0.524242:0.527616:0.008860:0.010222:0.005074:0.005074:0.009728:0.004505:0.009129:0.005807:0.004146:0.010222:0.009129:0.010252:0.004146:0.008860:0.004505:0.009803:0.010207:0.009803:0.005807:0.010222:0.002993:0.004146:0.004699:0.009803:0.004505:0.004146:0.010222:0.004146:0.011075:0.009728:0.012437:0.004146:0.013051:0.004505:0.010222:0.010252:0.002993:0.009129:0.010072:0.004146:0.007453:0.008022:0.005807:0.005074:0.009728:0.014038:0.004146:0.004146
Am :@0.884526:0.539871:0.913785:0.539871:0.913785:0.527616:0.884526:0.527616:0.011075:0.014038:0.004146
J Surg Pathol. :@0.524242:0.553103:0.625250:0.553103:0.625250:0.540848:0.524242:0.540848:0.007214:0.004146:0.007453:0.009100:0.004505:0.010072:0.004146:0.008860:0.010222:0.005074:0.009129:0.009803:0.002993:0.004146:0.004146
2016;40:244:@0.625250:0.553103:0.708163:0.553103:0.708163:0.540848:0.625250:0.540848:0.008291:0.008291:0.008291:0.008291:0.004146:0.008291:0.008291:0.004146:0.008291:0.008291:0.008291
Table 2. Pretreatment risk stratification for prostate cancer:@0.084242:0.599152:0.607434:0.599152:0.607434:0.583118:0.084242:0.583118:0.007889:0.012508:0.012508:0.004426:0.012123:0.005195:0.010583:0.005195:0.005195:0.010583:0.005965:0.012123:0.005580:0.005965:0.012123:0.012508:0.005580:0.017895:0.012123:0.011353:0.005580:0.005195:0.005965:0.004426:0.008274:0.010968:0.005195:0.008274:0.005580:0.005965:0.012508:0.005580:0.004426:0.004907:0.004897:0.012123:0.012508:0.005580:0.004426:0.012123:0.011353:0.005195:0.005195:0.012123:0.005965:0.005195:0.012508:0.005965:0.012123:0.008274:0.005580:0.012508:0.005580:0.012123:0.005195:0.012123:0.012508:0.011353:0.012123:0.012123:0.006158
Risk group:@0.093868:0.629904:0.188348:0.629904:0.188348:0.613870:0.093868:0.613870:0.010968:0.004426:0.008274:0.010968:0.005195:0.012508:0.005965:0.012123:0.011353:0.012700
Clinical stage:@0.301185:0.629904:0.426069:0.629904:0.426069:0.613870:0.301185:0.613870:0.014817:0.004426:0.004426:0.011353:0.004426:0.012123:0.012508:0.004426:0.005195:0.008274:0.005580:0.012508:0.012508:0.012315
Gleason Score:@0.508503:0.629904:0.642815:0.629904:0.642815:0.613870:0.508503:0.613870:0.015971:0.004426:0.012123:0.012508:0.008274:0.012123:0.011353:0.005195:0.009814:0.012123:0.012123:0.005965:0.012315
Serum PSA:@0.715821:0.629904:0.812802:0.629904:0.812802:0.613870:0.715821:0.613870:0.009814:0.012123:0.005965:0.011353:0.017895:0.005195:0.010583:0.009814:0.014239
Standard risk groups:@0.093887:0.652328:0.283232:0.652328:0.283232:0.636294:0.093887:0.636294:0.010006:0.005773:0.012700:0.011545:0.012700:0.012700:0.006158:0.012700:0.005388:0.006158:0.004618:0.008467:0.011161:0.005388:0.012700:0.006158:0.012315:0.011545:0.012700:0.008467
Low-risk:@0.093887:0.674751:0.164526:0.674751:0.164526:0.658995:0.093887:0.658995:0.008890:0.012604:0.015990:0.006388:0.005792:0.003848:0.007466:0.009660
T1c-T2a:@0.301205:0.674751:0.370901:0.674751:0.370901:0.658995:0.301205:0.658995:0.008197:0.010660:0.012450:0.006388:0.008197:0.010660:0.013143
≤6:@0.508522:0.674751:0.529747:0.674751:0.529747:0.658995:0.508522:0.658995:0.010564:0.010660
<10 ng/mL:@0.715840:0.674751:0.814188:0.674751:0.814188:0.658995:0.715840:0.658995:0.011661:0.010660:0.010660:0.005330:0.011738:0.012950:0.008409:0.018049:0.008890
Intermediate-risk:@0.093906:0.697174:0.248255:0.697174:0.248255:0.681418:0.093906:0.681418:0.004349:0.011738:0.006523:0.012508:0.006317:0.018049:0.012508:0.013181:0.003848:0.013143:0.006523:0.012508:0.006388:0.005792:0.003848:0.007466:0.009660
T2b:@0.301224:0.697174:0.333205:0.697174:0.333205:0.681418:0.301224:0.681418:0.008197:0.010660:0.013123
7:@0.508541:0.697174:0.519202:0.697174:0.519202:0.681418:0.508541:0.681418:0.010660
10 to 20 ng/mL:@0.715859:0.697174:0.853654:0.697174:0.853654:0.681418:0.715859:0.681418:0.010660:0.010660:0.005330:0.006523:0.012604:0.005330:0.010660:0.010660:0.005330:0.011738:0.012950:0.008409:0.018049:0.008890
High-risk:@0.093925:0.719598:0.168759:0.719598:0.168759:0.703842:0.093925:0.703842:0.013143:0.003848:0.012950:0.011738:0.006388:0.005792:0.003848:0.007466:0.009660
T2c:@0.301243:0.719598:0.332550:0.719598:0.332550:0.703842:0.301243:0.703842:0.008197:0.010660:0.012450
8 to 10:@0.508561:0.719598:0.570329:0.719598:0.570329:0.703842:0.508561:0.703842:0.010660:0.005330:0.006523:0.012604:0.005330:0.010660:0.010660
Risk groupings used by Memorial Sloan-Kettering and Seattle groups:@0.093945:0.742021:0.728944:0.742021:0.728944:0.725988:0.093945:0.725988:0.011161:0.004618:0.008467:0.011161:0.005388:0.012700:0.006158:0.012315:0.011545:0.012700:0.004618:0.011545:0.012700:0.008467:0.005388:0.011545:0.008467:0.012315:0.012700:0.005388:0.012700:0.011161:0.005388:0.017318:0.012315:0.018088:0.012315:0.006158:0.004618:0.012700:0.004618:0.005388:0.010006:0.004618:0.012315:0.012700:0.011545:0.008082:0.011930:0.012315:0.005773:0.005773:0.012315:0.006158:0.004618:0.011545:0.012700:0.005388:0.012700:0.011545:0.012700:0.005388:0.010006:0.012315:0.012700:0.005773:0.005773:0.004618:0.012315:0.005388:0.012700:0.006158:0.012315:0.011545:0.012700:0.008467
1, 2:@0.728848:0.736394:0.747493:0.736394:0.747493:0.727209:0.728848:0.727209:0.006215:0.003107:0.003107:0.006215
Low-risk:@0.093868:0.764435:0.164507:0.764435:0.164507:0.748680:0.093868:0.748680:0.008890:0.012604:0.015990:0.006388:0.005792:0.003848:0.007466:0.009660
≤T2a:@0.301185:0.764435:0.343750:0.764435:0.343750:0.748680:0.301185:0.748680:0.010564:0.008197:0.010660:0.013143
≤6:@0.508503:0.764435:0.529727:0.764435:0.529727:0.748680:0.508503:0.748680:0.010564:0.010660
<10 ng/mL:@0.715821:0.764435:0.814169:0.764435:0.814169:0.748680:0.715821:0.748680:0.011661:0.010660:0.010660:0.005330:0.011738:0.012950:0.008409:0.018049:0.008890
Intermediate-risk:@0.093887:0.786859:0.248236:0.786859:0.248236:0.771103:0.093887:0.771103:0.004349:0.011738:0.006523:0.012508:0.006317:0.018049:0.012508:0.013181:0.003848:0.013143:0.006523:0.012508:0.006388:0.005792:0.003848:0.007466:0.009660
One elevated risk factor: Clinical stage ≥T2a disease, Gleason :@0.301205:0.786859:0.880728:0.786859:0.880728:0.771103:0.301205:0.771103:0.016722:0.011738:0.012508:0.005330:0.012508:0.003848:0.012508:0.010660:0.013143:0.006523:0.012508:0.013181:0.005330:0.005792:0.003848:0.007466:0.009660:0.005330:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.005330:0.005330:0.015644:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.005330:0.007466:0.006523:0.013143:0.012950:0.012508:0.005330:0.010564:0.008197:0.010660:0.013143:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.005330:0.016779:0.003848:0.012508:0.013143:0.007466:0.012604:0.011738:0.005330
score ≥7, PSA ≥10 ng/mL:@0.301205:0.803025:0.526953:0.803025:0.526953:0.787269:0.301205:0.787269:0.007466:0.012450:0.012604:0.005711:0.012508:0.005330:0.010564:0.010660:0.005330:0.005330:0.011392:0.009583:0.014239:0.005330:0.010564:0.010660:0.010660:0.005330:0.011738:0.012950:0.008409:0.018049:0.008890
High-risk:@0.093887:0.825448:0.168721:0.825448:0.168721:0.809692:0.093887:0.809692:0.013143:0.003848:0.012950:0.011738:0.006388:0.005792:0.003848:0.007466:0.009660
Two elevated risk :@0.301205:0.825448:0.465758:0.825448:0.465758:0.809692:0.301205:0.809692:0.008324:0.015990:0.012604:0.005330:0.012508:0.003848:0.012508:0.010660:0.013143:0.006523:0.012508:0.013181:0.005330:0.005792:0.003848:0.007466:0.009660:0.005330
factors:@0.301205:0.841614:0.365224:0.841614:0.365224:0.825858:0.301205:0.825858:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466
PSA: prostate specific antigen; T1c: tumour identified by needle biopsy (e.g., because of elevated :@0.084242:0.870356:0.899031:0.870356:0.899031:0.856350:0.084242:0.856350:0.010126:0.008518:0.012657:0.004738:0.004738:0.011665:0.005068:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.004738:0.006636:0.011665:0.011118:0.011067:0.003421:0.004165:0.004165:0.011067:0.004738:0.011682:0.010434:0.005798:0.003421:0.011511:0.011118:0.010434:0.004738:0.004738:0.007286:0.009476:0.011067:0.004738:0.004738:0.005798:0.010399:0.016044:0.011203:0.010399:0.005148:0.004738:0.003421:0.011716:0.011118:0.010434:0.005798:0.003421:0.004165:0.004165:0.011118:0.011716:0.004738:0.011665:0.009168:0.004738:0.010434:0.011118:0.011118:0.011716:0.003421:0.011118:0.004738:0.011665:0.003421:0.011203:0.011665:0.006636:0.009168:0.004738:0.006312:0.011118:0.004738:0.011511:0.004738:0.004738:0.004738:0.011665:0.011118:0.011067:0.011682:0.010399:0.006636:0.011118:0.004738:0.011203:0.005371:0.004738:0.011118:0.003421:0.011118:0.009476:0.011682:0.005798:0.011118:0.011716:0.004738
PSA); T2a: tumour involves one-half of one lobe or less; T2b: tumour involves more than one-half of :@0.084242:0.884467:0.894453:0.884467:0.894453:0.870461:0.084242:0.870461:0.010126:0.008518:0.012657:0.006312:0.004738:0.004738:0.007286:0.009476:0.011682:0.004738:0.004738:0.005798:0.010399:0.016044:0.011203:0.010399:0.005148:0.004738:0.003421:0.010434:0.009476:0.011203:0.003421:0.009476:0.011118:0.006636:0.004738:0.011203:0.010434:0.011118:0.005679:0.010434:0.011682:0.003421:0.005371:0.004738:0.011203:0.005371:0.004738:0.011203:0.010434:0.011118:0.004738:0.003421:0.011203:0.011665:0.011118:0.004738:0.011203:0.005148:0.004738:0.003421:0.011118:0.006636:0.006636:0.004738:0.004738:0.007286:0.009476:0.011665:0.004738:0.004738:0.005798:0.010399:0.016044:0.011203:0.010399:0.005148:0.004738:0.003421:0.010434:0.009476:0.011203:0.003421:0.009476:0.011118:0.006636:0.004738:0.016044:0.011203:0.005006:0.011118:0.004738:0.005798:0.010434:0.011682:0.010434:0.004738:0.011203:0.010434:0.011118:0.005679:0.010434:0.011682:0.003421:0.005371:0.004738:0.011203:0.005371:0.004738
one lobe, but not both lobes; T2c: tumour involving both lobes:@0.084242:0.900636:0.597202:0.900636:0.597202:0.886630:0.084242:0.886630:0.011203:0.010434:0.011118:0.004738:0.003421:0.011203:0.011665:0.011118:0.004738:0.004738:0.011665:0.010399:0.005798:0.004738:0.010434:0.011203:0.005798:0.004738:0.011665:0.011203:0.005798:0.010434:0.004738:0.003421:0.011203:0.011665:0.011118:0.006636:0.004738:0.004738:0.007286:0.009476:0.011067:0.004738:0.004738:0.005798:0.010399:0.016044:0.011203:0.010399:0.005148:0.004738:0.003421:0.010434:0.009476:0.011203:0.003421:0.009476:0.003421:0.010434:0.011511:0.004738:0.011665:0.011203:0.005798:0.010434:0.004738:0.003421:0.011203:0.011665:0.011118:0.006636
Source: 1. Zelefsky M,:@0.084242:0.921875:0.237108:0.921875:0.237108:0.909620:0.084242:0.909620:0.007453:0.009803:0.009100:0.004505:0.009683:0.009728:0.004146:0.004146:0.008291:0.004146:0.004146:0.007184:0.009728:0.002993:0.009728:0.004699:0.005807:0.007513:0.008022:0.004146:0.013754:0.004146
 et al. Int J Radiat Oncol Biol Phys.:@0.237093:0.921875:0.480026:0.921875:0.480026:0.909620:0.237093:0.909620:0.004146:0.009728:0.005074:0.004146:0.010222:0.002993:0.004146:0.004146:0.003382:0.009129:0.005074:0.004146:0.007214:0.004146:0.009085:0.010222:0.010252:0.002993:0.010222:0.005074:0.004146:0.013006:0.009129:0.009683:0.009803:0.002993:0.004146:0.008591:0.002993:0.009803:0.002993:0.004146:0.008860:0.009129:0.008022:0.005807:0.004146
 2000;47:1261. 2. Blasko J,:@0.480011:0.921875:0.660670:0.921875:0.660670:0.909620:0.480011:0.909620:0.004146:0.008291:0.008291:0.008291:0.008291:0.004146:0.008291:0.008291:0.004146:0.008291:0.008291:0.008291:0.008291:0.004146:0.004146:0.008291:0.004146:0.004146:0.008591:0.002993:0.010222:0.005807:0.007513:0.009803:0.004146:0.007214:0.004146
 et al. Int J Radiat Oncol Biol Phys. :@0.660685:0.921875:0.907764:0.921875:0.907764:0.909620:0.660685:0.909620:0.004146:0.009728:0.005074:0.004146:0.010222:0.002993:0.004146:0.004146:0.003382:0.009129:0.005074:0.004146:0.007214:0.004146:0.009085:0.010222:0.010252:0.002993:0.010222:0.005074:0.004146:0.013006:0.009129:0.009683:0.009803:0.002993:0.004146:0.008591:0.002993:0.009803:0.002993:0.004146:0.008860:0.009129:0.008022:0.005807:0.004146:0.004146
 :@0.701139:0.921875:0.705284:0.921875:0.705284:0.909620:0.701139:0.909620:0.004146
2000;48:111:@0.084242:0.935107:0.167156:0.935107:0.167156:0.922852:0.084242:0.922852:0.008291:0.008291:0.008291:0.008291:0.004146:0.008291:0.008291:0.004146:0.008291:0.008291:0.008291